1. Treatment of Allosensitized Patients Receiving Allogeneic Transplantation
- Author
-
Ciurea, Stefan O, Malki, Monzr M Al, Kongtim, Piyanuch, Zou, Jun, Aung, Fleur M, Rondon, Gabriela, Chen, Julianne, Taniguchi, Michiko, Otoukesh, Salman, Nademanee, Auayporn, Forman, Stephen J, Champlin, Richard E, Gendzekhadze, Ketevan, and Cao, Kai
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Clinical Research ,Stem Cell Research ,Transplantation ,Female ,HLA Antigens ,Hematopoietic Stem Cell Transplantation ,Humans ,Male ,Middle Aged ,Rituximab ,Tissue Donors ,Transplantation ,Homologous ,Cardiovascular medicine and haematology - Abstract
Donor-specific anti-HLA antibodies (DSAs) are a major cause of engraftment failure in patients receiving haploidentical stem cell transplantation (HaploSCT). Effective treatments are needed for these patients, who often have no other donor options and/or are in need to proceed urgently to transplantation. We studied a multimodality treatment with alternate-day plasma exchange (PE), rituximab, intravenous γ globulin (IVIg) and an irradiated donor buffy coat for patients with DSAs at 2 institutions. Thirty-seven patients with a median age of 51 years were treated with this desensitization protocol. Treatment outcomes were compared with a control group of HaploSCT patients without DSAs (n = 345). The majority of patients in the DSA group were female (83.8% vs 37.1% in controls, P < .001) and received stem cells from a child as the donor (67.6% vs 44.1%, P = .002). Mean DSA level before and after desensitization was 10 198 and 5937 mean fluorescence intensity (MFI), respectively, with mean differences of 4030 MFI. Fourteen of 30 tested patients (46.7%) had C1q positivity, while 8 of 29 tested patients (27.6%) remained positive after desensitization. In multivariable analysis, patients with initial DSA > 20 000 MFI and persistent positive C1q after desensitization had a significantly lower engraftment rate, which resulted in significantly higher non-relapse mortality and worse overall survival (OS) than controls, whereas graft outcome and survival of patients with initial DSA < 20 000 MFI and those with negative C1q after treatment were comparable with controls. In conclusion, treatment with PE, rituximab, IVIg, and donor buffy coat is effective in promoting engraftment in patients with DSAs ≤20 000 MFI.
- Published
- 2021